ArticleJournal of cancer research and clinical oncology2009
Expression of anion exchanger 1 is associated with tumor progress in human gastric cancer.
Article in Journal of cancer research and clinical oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- Gene expression analysis revealed downregulation of complement receptor 1 in clonal B cells in cold agglutinin disease.Clinical and experimental immunology · 2024Article
- Chloride Channels and Transporters: Roles beyond Classical Cellular Homeostatic pH or Ion Balance in Cancers.Cancers · 2022Review
- Ion Channels, Transporters, and Sensors Interact with the Acidic Tumor Microenvironment to Modify Cancer Progression.Reviews of physiology, biochemistry and pharmacology · 2022Review
- Knockdown of RREB1 inhibits cell proliferation via enhanced p16 expression in gastric cancer.Cell cycle (Georgetown, Tex.) · 2021Article
- Bioactive Compounds from Marine Heterobranchs.Marine drugs · 2020Review
- CAR-T Cell Therapy-An Overview of Targets in Gastric Cancer.Journal of clinical medicine · 2020Review
- Physiological Significance of Ion Transporters and Channels in the Stomach and Pathophysiological Relevance in Gastric Cancer.Evidence-based complementary and alternative medicine : eCAM · 2020Review
- Diverse Stakeholders of Tumor Metabolism: An Appraisal of the Emerging Approach of Multifaceted Metabolic Targeting by 3-Bromopyruvate.Frontiers in pharmacology · 2019Review
- Anion exchanger 2 suppresses cellular movement and has prognostic significance in esophageal squamous cell carcinoma.Oncotarget · 2018Article
- Knockdown of anion exchanger 2 suppressed the growth of ovarian cancer cells via mTOR/p70S6K1 signaling.Scientific reports · 2017Article
- Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance.Medicinal research reviews · 2017Review
- Article
- Nitric oxide and pH modulation in gynaecological cancer.Journal of cellular and molecular medicine · 2016Review
- Article
- Does aberrant membrane transport contribute to poor outcome in adult acute myeloid leukemia?Frontiers in pharmacology · 2015Article
- Cellular physiological approach for treatment of gastric cancer.World journal of gastroenterology · 2014Review
- Regulation and roles of bicarbonate transporters in cancer.Frontiers in physiology · 2014Article
- Anti-tumour effects of small interfering RNA targeting anion exchanger 1 in experimental gastric cancer.British journal of pharmacology · 2012Article
- Article
- CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside.OncoimmunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAnion exchanger 1 (AE1) is a transmembrane glycoprotein which is abundantly expressed in erythrocyte plasma membrane and mediates the electroneutral exchange of Cl(-) and HCO(3) (-). We previously reported that the AE1 protein was unexpectedly expressed in the gastric and colonic cancer and take part in the carcinogenesis of the cancer cells. The aim of the present study is to determine the potential clinical implications of AE1 expression in gastric carcinoma.
methodsImmunohistochemistry assay was used to determine the expression of AE1 protein. The expression of AE1 in normal and malignant tissues from 286 patients with early and advanced gastric carcinoma was examined. The correlations of AE1 expression with clinicopathological parameters, including age, tumor size, location and subtypes, expression frequency, survival period and lymph metastasis were assessed by Chi-squared test and t test analysis.
resultsAE1 immunoreactivity was negative in normal gastric tissue. Positive immunostaining of AE1 was detected in gastric carcinoma regardless of the location. AE1 was most frequently expressed in the gastric antrum carcinoma compared with gastric body cancer (P = 0.034). Expression of AE1 was significantly associated with bigger tumor size, deeper invasion, shorter survival period, and non-lymph metastasis. In para-cancer tissues of intestinal-type gastric cancer, the expression frequency of AE1 was higher than that in diffuse-type (P = 0.011).
conclusionThe results showed a strong association of AE1 expression with the onset and progression of the gastric cancer and that may be helpful for improving the tumor classification and the treatment of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.